To include your compound in the COVID-19 Resource Center, submit it here.

FDA refuses Acorda's Inbrija NDA for PD

Acorda Therapeutics Inc. (NASDAQ:ACOR) said FDA issued a refusal to file letter to an NDA for Inbrija levodopa inhalation powder (CVT-301) to treat "off"

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE